Newly approved SRS agent, In- 111 pentetreoide (Octreoscan ) was employed in 11 patients with MTC: 6 men, and 5 women, mean age of 38 years (range 24 to 60 years). All patients had a prior history of thyroidectomy and abnormal calcitonin level and were reffered to investigate possible recurrence, residual disease, and/or extent of the disease. Patients were injected with approximately 5 mCi of In- 111pentetrotide, intravenously. Whole body planner images were performed at 4, 24 and 48 hours and SPECT images with a multidetector gamma camera at 24 and/0r 48 hours were obtained. Correlation were made with other imaging modalities (X- Ray, CT, MRI, US) and when available histopathologic reports. There were 8 SRS positive cases, and in 2 of these cases SRS showed lesions that were not visualized by other imaging modalities. SRS and other modalities did not show lesions in 3 patients. Calcitonin levels measured within 2 weeks of the scan renged from 57 to 71275 pg/ml (normal value M<26F>17). Mean calcitonin in SRS positive cases was 20,273, (ranging from 57 to 71275) significantly different from mean in SRS negative cases of 2170 (ranging from 1815 to 2350) at p<0.001. We conclude that SRS is capable of detecting residual and/or recurrent MTC when other imaging modalities are negative and the probability for detection lesions is increased with higher level of
calcitonin at the time of study.
These posters were displayed in the Exhibit Hall in Texas Ballroom IV, 29-30th of March 1996.
By: E.S. Delpassand , P. Bassa, W Broussard, E. Razmpa, T.P. Haynie, D.A. Podoloff. U. T. M. D. Anderson Cancer Center, Houston, Texas.
